About Nuclear pore complex protein Nup155
Nuclear pore complex protein Nup155 (NUP155) is a protein
from Homo sapiens identified by UniProt accession
O75694, 1391 residues long.
MolForge cross-references it against 0 known binders and
226 disease associations.
Target properties
| Protein name | Nuclear pore complex protein Nup155 |
|---|
| UniProt accession | O75694 |
|---|
| Gene | NUP155 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1391 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (226)
Diseases linked to this target (Open Targets).
- HIV infection · score 0.54
- influenza · score 0.54
- viral disease · score 0.53
- atrial fibrillation · score 0.49
- familial atrial fibrillation · score 0.39
- COVID-19 · score 0.37
- Histiocytosis · score 0.37
- low grade glioma · score 0.25
- breast adenocarcinoma · score 0.25
- lysosomal storage disease · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75694-F1 | alphafold | PREDICTED | 83.15 | — |
Amino-acid sequence (1391 residues)
MPSSLLGAAM PASTSAAALQ EALENAGRLI DRQLQEDRMY PDLSELLMVS APNNPTVSGM SDMDYPLQGP GLLSVPNLPE ISSIRRVPLP PELVEQFGHM QCNCMMGVFP PISRAWLTID SDIFMWNYED GGDLAYFDGL SETILAVGLV KPKAGIFQPH VRHLLVLATP VDIVILGLSY ANLQTGSGVL NDSLSGGMQL LPDPLYSLPT DNTYLLTITS TDNGRIFLAG KDGCLYEVAY QAEAGWFSQR CRKINHSKSS LSFLVPSLLQ FTFSEDDPIL QIAIDNSRNI LYTRSEKGVI QVYDLGQDGQ GMSRVASVSQ NAIVSAAGNI ARTIDRSVFK PIVQIAVIEN SESLDCQLLA VTHAGVRLYF STCPFRQPLA RPNTLTLVHV RLPPGFSASS TVEKPSKVHR ALYSKGILLM AASENEDNDI LWCVNHDTFP FQKPMMETQM TAGVDGHSWA LSAIDELKVD KIITPLNKDH IPITDSPVVV QQHMLPPKKF VLLSAQGSLM FHKLRPVDQL RHLLVSNVGG DGEEIERFFK LHQEDQACAT CLILACSTAA CDREVSAWAT RAFFRYGGEA QMRFPTTLPP PSNVGPILGS PVYSSSPVPS GSPYPNPSFL GTPSHGIQPP AMSTPVCALG NPATQATNMS CVTGPEIVYS GKHNGICIYF SRIMGNIWDA SLVVERIFKS GNREITAIES SVPCQLLESV LQELKGLQEF LDRNSQFAGG PLGNPNTTAK VQQRLIGFMR PENGNPQQMQ QELQRKFHEA QLSEKISLQA IQQLVRKSYQ ALALWKLLCE HQFTIIVAEL QKELQEQLKI TTFKDLVIRD KELTGALIAS LINCYIRDNA AVDGISLHLQ DICPLLYSTD DAICSKANEL LQRSRQVQNK TEKERMLRES LKEYQKISNQ VDLSNVCAQY RQVRFYEGVV ELSLTAAEKK DPQGLGLHFY KHGEPEEDIV GLQAFQERLN SYKCITDTLQ ELVNQSKAAP QSPSVPKKPG PPVLSSDPNM LSNEEAGHHF EQMLKLSQRS KDELFSIALY NWLIQVDLAD KLLQVASPFL EPHLVRMAKV DQNRVRYMDL LWRYYEKNRS FSNAARVLSR LADMHSTEIS LQQRLEYIAR AILSAKSSTA ISSIAADGEF LHELEEKMEV ARIQLQIQET LQRQYSHHSS VQDAVSQLDS ELMDITKLYG EFADPFKLAE CKLAIIHCAG YSDPILVQTL WQDIIEKELS DSVTLSSSDR MHALSLKIVL LGKIYAGTPR FFPLDFIVQF LEQQVCTLNW DVGFVIQTMN EIGVPLPRLL EVYDQLFKSR DPFWNRMKKP LHLLDCIHVL LIRYVENPSQ VLNCERRRFT NLCLDAVCGY LVELQSMSSS VAVQAITGNF KSLQAKLERL H
Explore Nuclear pore complex protein Nup155 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets